Correlation Between Kilitch Drugs and EPL
Specify exactly 2 symbols:
By analyzing existing cross correlation between Kilitch Drugs Limited and EPL Limited, you can compare the effects of market volatilities on Kilitch Drugs and EPL and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kilitch Drugs with a short position of EPL. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kilitch Drugs and EPL.
Diversification Opportunities for Kilitch Drugs and EPL
0.13 | Correlation Coefficient |
Average diversification
The 3 months correlation between Kilitch and EPL is 0.13. Overlapping area represents the amount of risk that can be diversified away by holding Kilitch Drugs Limited and EPL Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on EPL Limited and Kilitch Drugs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kilitch Drugs Limited are associated (or correlated) with EPL. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of EPL Limited has no effect on the direction of Kilitch Drugs i.e., Kilitch Drugs and EPL go up and down completely randomly.
Pair Corralation between Kilitch Drugs and EPL
Assuming the 90 days trading horizon Kilitch Drugs Limited is expected to generate 0.75 times more return on investment than EPL. However, Kilitch Drugs Limited is 1.33 times less risky than EPL. It trades about 0.1 of its potential returns per unit of risk. EPL Limited is currently generating about -0.11 per unit of risk. If you would invest 31,745 in Kilitch Drugs Limited on December 30, 2024 and sell it today you would earn a total of 4,515 from holding Kilitch Drugs Limited or generate 14.22% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Kilitch Drugs Limited vs. EPL Limited
Performance |
Timeline |
Kilitch Drugs Limited |
EPL Limited |
Kilitch Drugs and EPL Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Kilitch Drugs and EPL
The main advantage of trading using opposite Kilitch Drugs and EPL positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kilitch Drugs position performs unexpectedly, EPL can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPL will offset losses from the drop in EPL's long position.Kilitch Drugs vs. LT Technology Services | Kilitch Drugs vs. Nucleus Software Exports | Kilitch Drugs vs. Servotech Power Systems | Kilitch Drugs vs. Sintex Plastics Technology |
EPL vs. Pilani Investment and | EPL vs. Kalyani Steels Limited | EPL vs. Mask Investments Limited | EPL vs. Tube Investments of |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Complementary Tools
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Bonds Directory Find actively traded corporate debentures issued by US companies |